Affiliation:
1. Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP‐HP, Centre de Recherche Saint‐Antoine INSERM UMRs938 Sorbonne Université Paris France
Abstract
Induction chemotherapy followed by autologous haematopoietic cell transplantation and post‐transplant therapy (including maintenance therapy with or without prior consolidation) is still considered as the standard of care for newly diagnosed young and fit multiple myeloma patients. Over the last years, superiority of quadruplet regimens for induction was established, with the addition of an anti‐CD38 monoclonal antibody to triplet regimen including a proteasome inhibitor, an IMiD (thalidomide or lenalidomide) or cyclophosphamide, and dexamethasone. Given quadruplet induction regimens are associated with deep response, including a high‐rate of sustained measurable residual disease negativity in a significant proportion of patients, they are now recommended for induction chemotherapy when available.